Tag - lung cancer

Developments

BeyondSpring prices $35-million equity offering

BeyondSpring (NASDAQ:BYSI) priced a public offering of 2,058,825 ordinary shares at $17 apiece for expected gross proceeds of $35-million. The offering was led by Decheng Capital. The underwriter has a 30-day option to...

July 17, 2019

Feature

ARIAD hopes to launch second oncology drug in early 2017

By Len Zehr ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small...

May 17, 2016

Tag - lung cancer

BeyondSpring prices $35-million equity offering

ARIAD hopes to launch second oncology drug in early 2017

General

More